Valbiotis Management

Management criteria checks 4/4

Valbiotis' CEO is Sebastien Peltier, appointed in Mar 2017, has a tenure of 7.67 years. total yearly compensation is €301.00K, comprised of 59.8% salary and 40.2% bonuses, including company stock and options. directly owns 4% of the company’s shares, worth €787.40K. The average tenure of the management team and the board of directors is 5.8 years and 7.1 years respectively.

Key information

Sebastien Peltier

Chief executive officer

€301.0k

Total compensation

CEO salary percentage	59.8%
CEO tenure	7.7yrs
CEO ownership	4.0%
Management average tenure	5.8yrs
Board average tenure	7.1yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Sebastien Peltier's remuneration changed compared to Valbiotis's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2024	n/a	n/a	-€9m
Mar 31 2024	n/a	n/a	-€8m
Dec 31 2023	€301k	€180k	-€7m
Sep 30 2023	n/a	n/a	-€8m
Jun 30 2023	n/a	n/a	-€9m
Mar 31 2023	n/a	n/a	-€11m
Dec 31 2022	€318k	€180k	-€12m
Sep 30 2022	n/a	n/a	-€11m
Jun 30 2022	n/a	n/a	-€10m
Mar 31 2022	n/a	n/a	-€9m
Dec 31 2021	€259k	€180k	-€9m

Compensation vs Market: Sebastien's total compensation ($USD316.88K) is about average for companies of similar size in the French market ($USD326.24K).

Compensation vs Earnings: Sebastien's compensation has been consistent with company performance over the past year.

CEO

Sebastien Peltier (46 yo)

7.7yrs

Tenure

€301,000

Compensation

Mr. Sebastien Peltier, Ph D., HDR serves as the Chief Executive Officer of Valbiotis SA and is Co-Founder of Valbiotis. Mr. Peltier has been Member of Management Board of Valbiotis SA from March 7, 2017 an...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Sebastien Peltier	Co-Founder	7.7yrs	€301.00k	4% € 787.4k
Sebastien Bessy	COO & Member of the Management Board	3.4yrs	€295.00k	0.035% € 6.9k
Pascal Sirvent	CSO & Member of the Management Board	6.2yrs	€236.00k	0.12% € 24.0k
Murielle Cazaubiel	CMO & Member of the Management Board	5.8yrs	€255.00k	0.0026% € 511.5
Stanislas Sordet	CFO & Member of Management Board	less than a year	no data	no data
Charlotte Jezequel	Director of HR & Member of Management Board	1.8yrs	no data	no data
Josep Infesta	Head of Global Business Development	5.8yrs	no data	no data

5.8yrs

Average Tenure

Experienced Management: ALVAL's management team is seasoned and experienced (5.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Agnes Tixier	Member of Supervisory Board	5.7yrs	no data	no data
Laurent Levy	Chairman of Supervisory Board	7.7yrs	no data	no data
Nathalie Boisseau	Member of Scientific & Medical Board	no data	no data	no data
Jean-Marie Bard	Member of Scientific & Medical Board	no data	no data	no data
Samy Hadjadj	Member of Scientific & Medical Board	no data	no data	no data
Thierry Maugard	Member of Scientific & Medical Board	no data	no data	no data
Bruno Guigas	Member of Scientific & Medical Board	no data	no data	no data
André Marette	Member of Scientific & Medical Board	no data	no data	no data
Jean Zetlaoui	Member of Supervisory Board	7.1yrs	no data	no data

7.1yrs

Average Tenure

Experienced Board: ALVAL's board of directors are considered experienced (7.1 years average tenure).

Valbiotis Management

Management criteria checks 4/4

Key information

Recent management updates

Valbiotis SA, Annual General Meeting, Jun 25, 2024

Valbiotis Appoints Frédéric PELONG to Board of Directors

Valbiotis Appoints Frédéric PELONG to Board of Directors

No independent directors

Valbiotis Announces Board of Directors Changes

Recent updates

New minor risk - Profitability

Price target increased by 25% to €6.35

Is Valbiotis (EPA:ALVAL) A Risky Investment?

Consensus EPS estimates fall by 18%

Price target decreased by 13% to €8.60

Valbiotis SA, Annual General Meeting, Jun 25, 2024

Full year 2023 earnings released

New minor risk - Shareholder dilution

New minor risk - Profitability

Price target decreased by 10% to €10.60

Consensus revenue estimates decrease by 30%

Valbiotis SA has filed a Follow-on Equity Offering in the amount of €15.000001 million.

Valbiotis SA Presents the Full Results of the Phase II/III REVERSE-IT Study: Impressive Efficacy of TOTUM 63 Against Prediabetes and the Early Stages of Type 2 Diabetes, a First for a Non-drug Active Substance

Consensus EPS estimates fall by 99%

Consensus revenue estimates decrease by 32%

Price target increased by 7.5% to €11.93

Consensus EPS estimates upgraded to €0.65 loss

Valbiotis Announces the Large Success of the REVERSE-IT International Multicentric Phase II/III Clinical Study on TOTUM-63

Rock star Growth Puts Valbiotis (EPA:ALVAL) In A Position To Use Debt

Forecast breakeven date pushed back to 2025

Full year 2022 earnings released

Valbiotis Announces Positive Results in the Bioavailability and Mode of Action TOTUM--854 Clinical Study, Against High Blood Pressure

Forecast breakeven date pushed back to 2024

Price target decreased to €11.83

Forecast to breakeven in 2023

Valbiotis SA announced that it has received €9.7 million in funding

Valbiotis SA Presents Additional Positive Results from the HEART Clinical Study on TOTUM•070 for Hypercholesterolemia

Consensus forecasts updated

Forecast breakeven date moved forward to 2023

Price target decreased to €13.67

First half 2022 earnings released

Consensus forecasts updated

Forecast to breakeven in 2023

Valbiotis Appoints Frédéric PELONG to Board of Directors

Valbiotis Appoints Frédéric PELONG to Board of Directors

Valbiotis Announces Completion of Recruitment for the Phase Ii/Iii Reverse-It Clinical Study with Totum•63 Against Prediabetes, in Partnership with Nestlé Health Science

Consensus forecasts updated

Valbiotis Announces the Major Success of the Phase II Heart Clinical Study the Patented Plant-Based Active Substance Totum•070 Proves Its Efficacy Against Hypercholesterolemia, A Cardiovascular Risk Factor

Is Valbiotis (EPA:ALVAL) Using Debt In A Risky Way?

Forecast to breakeven in 2023

No independent directors

Valbiotis SA Announces the Positive Results of Its Clinical Study on the Bioavailability and Mode of Action of TOTUM•070, Against Hypercholesterolemia

Consensus forecasts updated

Full year 2021 earnings: Revenues miss analyst expectations

Valbiotis Announces Board of Directors Changes

Valbiotis SA to Report Fiscal Year 2021 Results on Mar 15, 2022

Valbiotis Announces Approval to Launch the Two Phase II/III Insight and Insight 2 Clinical Studies, the Last Step in the Development of Totum•854 for the Reduction of Blood Pressure

Consensus forecasts updated

Forecast to breakeven in 2023

Valbiotis Submits to the Competent Authorities the Three Clinical Protocols for TOTUM•854 Indicated in the Reduction of Blood Pressure and Presents its Comprehensive Clinical Development Plan

First half 2021 earnings released

Valbiotis Announces the Publication of the First Scientific Papers on TOTUM•63 in Three International Journals, Elucidating Its Multitarget Mode of Action

Full year 2020 earnings released

Valbiotis SA to Report First Half, 2021 Results on Sep 30, 2021

Valbiotis Selected to Present TOTUM-854 Results on Arterial Hypertension

Valbiotis SA (EPA:ALVAL) Is Expected To Breakeven In The Near Future

Valbiotis SA Announces the First Patient’s First Visit in the Phase II HEART Clinical Study on TOTUM-070 and Steps up Its Research Program Against Hypercholesterolemia in 2021

Valbiotis Authorizes to Launch Heart, the Phase II Multi-Center Clinical Study with TOTUM-070, for the Reduction of Blood LDL-Cholesterol Levels

New 90-day high: €7.80

New 90-day high: €6.90

New 90-day high: €6.60

VALBIOTIS Presents the First Market Data on Untreated LDL-hypercholesterolemia For TOTUM-070, And Announces the Initiation of The Phase II Clinical Study HEART

New 90-day high: €4.85

VALBIOTIS Announces the Selection of 3 Studies on TOTUM-63 by the European Association for the Study of Diabetes

New 90-day high: €4.83

Valbiotis SA announced that it has received €1.999998 million in funding from Amiral Gestion SA

New 90-day high - €4.66

CEO Compensation Analysis

CEO

Tenure